Special Issue

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

A Special Issue of Metabolism and Target Organ Damage

ISSN 2769-6375 (Online)

Submission deadline: 30 Jun 2025

Guest Editor(s)

Assoc. Prof. Gyorgy Baffy
Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.
Prof. Amedeo Lonardo
Operating Unit of Metabolic Syndrome, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara (-2023), Modena, Italy.
Prof. Ralf Weiskirchen

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Rheinisch-Westfälische Technische Hochschule (RWTH), University Hospital Aachen, Aachen, Germany.

Special Issue Introduction

Liver fibrosis is the result of an excessive wound-healing process triggered by chronically acting physical, biochemical, and cellular stimuli in the liver. Initially, liver fibrosis develops silently, but as it progresses, mechanobiological forces increasingly prevail and significant architectural changes lead to liver cirrhosis and may culminate in complications such as clinically significant portal hypertension, liver failure, and hepatocellular carcinoma.

Given the increasing impact of liver fibrosis on clinical workload and health care costs worldwide, this Special Issue focuses specifically on liver fibrosis resulting from metabolic dysfunction.

We invite manuscripts that address any aspects of this condition, including epidemiology, pathogenesis, diagnosis, and management. We are particularly interested in histological and non-invasive diagnostic strategies, such as algorithms, biomarkers, imaging techniques, and the emerging role of artificial intelligence in these efforts. Additionally, we welcome submissions on molecular and cellular mechanisms, clinical observations, experimental evidence, and outcomes research related to liver fibrosis and its impact on cardiovascular-renal-metabolic health, all-cause mortality, and the development of hepatic and extrahepatic cancers. We also encourage submissions on all aspects of detection and treatment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease.

Related webinar



Link: https://www.oaepublish.com/webinars/mtod.274

Submission Deadline

30 Jun 2025

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/mtod/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mtod&SpecialIssueId=mtod240507
Submission Deadline: 30 Jun 2025
Contacts: Lily Luo, Assistant Editor, lily@oae-publish.com

Published Articles

Copper and liver fibrosis in MASLD: the two-edged sword of copper deficiency and toxicity
Open Access Review 20 Sep 2024
Views: Downloads:
Download PDF
Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis
Open Access Review 21 Aug 2024
Views: Downloads:
Download PDF
Metabolism and Target Organ Damage
ISSN 2769-6375 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/